Newsletter · · Ashutosh Agarwal

Drug Tariffs, the ACA's Quiet Unwind, and GLP-1 Access - Healthcare Policy: Drug Pricing, IRA & Managed Care - Week of July 25, 2026

A synthesis of institutional healthcare podcasts on the proposed 100% generic-drug tariff, the ACA's quiet unwind through Medicaid paperwork and payer exits, and who actually pays for GLP-1s, for the week of July 25, 2026.

Healthcare Policy: Drug Pricing, IRA & Managed Care

Week of July 25, 2026: Drug Tariffs, the ACA's Quiet Unwind, and GLP-1 Access

Intro

This week the loudest healthcare news wasn't a drug price negotiation or a rate notice. It was quieter, and in some ways more consequential: a plan to slap a 100% tariff on the generic pills that fill nine out of ten American prescriptions, a Medicaid paperwork rule that could push millions off coverage, and a hospital giant cutting its profit forecast because fewer people have insurance. Underneath it all runs one theme the podcasts kept circling back to: the government is squeezing what it pays for healthcare from every direction at once, and companies are starting to show the marks.

There was also plenty on GLP-1s (the wildly popular weight-loss and diabetes drugs like Ozempic, Wegovy, and Zepbound), but this week the interesting angle was who pays for them, not how well they work. Let's get into it.

TL;DR

  • Trump threatened a 100% tariff on imported generic drugs, doubling to 200% the year after, a move aimed at forcing manufacturing back to the US, but one that reporters warn could raise prices and cause shortages of the cheap medicines most Americans rely on.
  • The Affordable Care Act is being taken apart quietly, not repealed outright: expired subsidies, sky-high premiums, new Medicaid paperwork hurdles, and payers exiting government business. Hospital operator HCA already cut its 2026 forecast because of it.
  • Insurers still barely cover GLP-1s, leaving most patients paying ~$200+ a month out of pocket, but Medicare just cracked the door open for seniors, which could eventually mean millions of new covered patients.

What's new

1. A 100% tariff on generic drugs, the cheap medicines almost everyone takes. On Bloomberg Daybreak: US Edition (July 22), Bloomberg reporter John Tucker laid out the plan straight from a Trump social-media post: generic drug makers get two years to move production to the US "or face a 100% import duty," starting August of next year, and "the tariffs would then double to 200% the following year." Why it matters: generics "account for more than 90% of US prescriptions." Tucker's warning was blunt: these tariffs "would raise costs for manufacturers who already operate on pretty thin margins, risking higher prices and potential shortages," and "it's unclear how forcing companies to make more medicines in the US will help bring prices down, given the lower costs of labor and manufacturing in established locations like India." In plain terms: the policy is sold as tough-on-China industrial strategy, but the bill could land on patients at the pharmacy counter. (Reporter/pundit view.)

2. Medicaid's new "prove you're too sick to work" rule sparks a 26-state lawsuit. On Marketplace (July 23), Dr. Mohamed Dar, former medical director of the Massachusetts Medicaid program, now chief medical officer of a 25-clinic community health network, so someone who actually runs this plumbing, described a policy whiplash. For months, federal officials said existing records would be enough to prove someone was too medically frail to work. Then in June, CMS reversed course: starting in 2027, many patients will also need fresh documentation, like a doctor's note. Massachusetts, 24 other states, and DC are now suing to stop it. Maryland said in court filings it already spent "more than $30 million" building systems to use the data it has, and the new test means "another $2 million at least." Dar's description of what states were handed: "a bureaucratic train wreck of there are no train tracks, there is no route, just go north." Why it matters: the changes "could jeopardize coverage for 7 million people," and the Commonwealth Fund estimates hospitals in states with more generous Medicaid "could see operating margins fall by 11% to 30%." His line stuck: "Never have we hit our own healthcare system with such a battering ram." (Operator/insider view.)

3. CMS is bringing back a Star Ratings measure, and it lands on already-squeezed insurers. On the Pharmacy Podcast Network (July 22), two executives from Outcomes, Ross Frey and payer-products director Cindy Hendry, who sell services to Medicare Advantage plans, dug into the 2027 advance notice. The headline for insiders: CMS formalized its intent to return the "CMR completion rate" (a medication-review quality measure) to the Star Ratings program for measure year 2027, after two years on a low-stakes "display page." Star Ratings matter because they drive real Medicare Advantage bonus dollars. Hendry's framing of the pressure plans are under was candid: "margins are reducing... our sources of revenue, which used to have some room or flexibility, they're starting to flatten," even as "the denominator for the CMR measure is going to be increasing. So now you're doing more, you're deploying a higher cost program." Why it matters: it's another small turn of the screw on Medicare Advantage profitability, do more work, spend more, for a rating that used to be an easier "give me." (Operator/insider view, payer side.)

4. Hospitals are shifting outpatient, and a Medicare prior-auth pilot survived. On Health:Further (July 19), the hosts, investors, one an HCA shareholder, walked through a busy week of operator results (more on the names below), plus two structural signals. First, from Kaufman Hall's national hospital flash report: outpatient revenue per calendar day rose 8% year-over-year through May, outpacing the 5% rise in inpatient revenue, with inpatient discharges roughly flat, care keeps drifting out of the hospital bed and into same-day settings. Second, Senate Republicans killed an effort to end the "WISER" Medicare prior-authorization pilot (Wasteful and Inappropriate Service Reduction), so it will roll out and add prior authorization to some Medicare services in six states. As one host put it, "this is more proof that the Trump administration and the Republicans are very, very serious about curbing the healthcare expense of the country." (Investor/pundit view of operator news.)

5. Insurers still won't cover GLP-1s, but Medicare cracked the door. On Bloomberg Intelligence (July 23), Bloomberg healthcare reporter Madison Muller explained the coverage gap that still defines this market: insurers are "still not widely covering these, which is pretty different than other chronic conditions." Out of pocket, patients pay "a couple hundred dollars a month," better than the "over a thousand dollars a month" list price of a couple years ago, after the drugmakers cut cash-pay prices, but still out of reach for many. The policy wrinkle: "Medicare recently started covering these drugs for people 65 and older with certain health conditions," which is "expected to open access to potentially millions more people." She also flagged that Eli Lilly plans to file its next-generation shot, retatrutide (up to ~30% weight loss in trials), for FDA approval in the first quarter of 2027. (Reporter/pundit view.)

The debate

Are drug prices high because innovation is expensive, or because the system is gamed?

The "it's the patents" side. On Mostly Economics (July 23), drug-access advocate Tahir Amin made the case that America overpays because companies stack legal protections, not because the science keeps getting costlier. His star exhibit was AbbVie's Humira: even by the AbbVie CEO's own 2019 Senate testimony, the company held "136 granted patents" around the drug (Amin's group counted far more), which pushed protection from an original expiry around 2016 out to 2034. AbbVie then settled with biosimilar rivals to let them in around 2023, buying, in Amin's telling, "an extra seven years," a window in which it made "114 billion in revenue" while the price rose "almost 470%." He argues the same playbook repeats, pointing to Merck moving Keytruda from an IV to an under-the-skin version to extend its monopoly and calling it "innovation," and that the industry hides behind the word "value" to justify prices while the actual cost to manufacture keeps falling. His provocation: separate real invention from clever life-cycle management.

The "don't kill the goose" side. The counterpoint showed up on The Heart of Healthcare (July 20), where author Eric Ries used Novo Nordisk to argue that squeezing pharma too hard, or running it purely for short-term shareholders, can destroy enormous value. Novo's unusual structure (a nonprofit foundation controls the company) let its board reject a mega-merger in the early 2000s that, Ries says, would have shut down a 13-year-old research program that had borne no fruit yet. That program became GLP-1. From the moment Novo's market cap topped the entire GDP of Denmark to the board saying no to the deal, he argues, the company created "more than 500 billion dollars of shareholder value." His point cuts against pure cost-cutting: the drugs everyone now wants to make cheaper only exist because someone was patient and well-funded enough to keep going. Note both voices here are outside experts and advocates, not company operators: steel-manned, but pundit-grade.

Where they actually agree: neither disputes that GLP-1s cost a small fraction of their price to manufacture. The fight is over what that gap pays for: future breakthroughs, or extraction.

The names in play

  • HCA Healthcare (HCA), the clearest single-company casualty this week. On Health:Further, the hosts detailed HCA trimming its 2026 outlook, citing roughly a $400 million hit in the second quarter tied to insurance-coverage losses (as the ACA marketplace shrinks), and a hit on the order of $1.1 billion over the next four years. Their read: HCA is an exceptionally well-run operator with a strong balance sheet that will absorb this, but "if HCA can't navigate this without having to restate... what is hard for HCA could be ending for most hospitals."
  • UnitedHealth Group (UNH), the counterweight. The same hosts noted UNH raised its 2026 guidance again as cost controls kicked in, with second-quarter profit spiking to about $5.5 billion, crediting the company's returning CEO with "turning the ship" after a brutal 2024–25.
  • Elevance (ELV), softer. The hosts flagged Elevance previewing Medicaid exits as profit slipped, even the big Blues-based insurer is stepping back from government business.
  • CVS Health / Caremark (CVS), its Caremark unit reached a settlement with the FTC over an insulin suit, with concessions around lower costs and including "Trump RX." The hosts read it as part of a "drumbeat" neutralizing the profitability of large, vertically integrated pharmacy-benefit machines.
  • AbbVie (ABBV), Merck (MRK), Eli Lilly (LLY), Novo Nordisk (NVO), featured in the pricing and GLP-1 debates above: AbbVie as the patent-stacking case study, Merck's Keytruda life-cycle move, Lilly's retatrutide filing timeline, and Novo's governance story.

Read-throughs

  • PBMs (pharmacy middlemen): The CVS Caremark settlement with the FTC over insulin, plus the hosts' view that "the existence of a PBM with a limited formulary driving price concessions and high profits... is ending quickly," points to continued regulatory pressure on the pharmacy-benefit profit model.
  • Generics & biosimilars: The 100% (rising to 200%) generic-drug tariff is the week's biggest wildcard, potentially bullish for US-based manufacturing but a real risk of shortages and higher costs given how much supply comes from India. Separately, AbbVie's Humira story is a reminder of how long brand-name patent thickets can delay biosimilar competition.
  • Ex-US supply: India sits squarely in the tariff crosshairs as the low-cost source of much US generic supply.
  • Medicaid & exchange insurers: Payers are retreating from government business across the board: Medicaid, Medicare Advantage, and the ACA marketplace. Fewer competitors means thinner, weaker networks; Elevance's Medicaid pullback is the marquee example.
  • Optum-style services: Regulatory pressure on vertically integrated PBM/insurer/services stacks (via the FTC insulin action) is the read-through for the big services arms.
  • Hospitals: Double blow: coverage losses shrinking the paying-patient pool (HCA's cut is the tell) and a durable shift from inpatient to outpatient care. Rural and lower-margin systems are most exposed; the Medicaid "medically frail" rule and the Commonwealth Fund's 11–30% margin-hit estimate raise the stakes further.
  • GLP-1 exposure: The bottleneck remains insurance coverage, not demand. Medicare's new coverage for seniors with certain conditions, plus the July 1 Medicare Part D "bridge" easing access to weight-management drugs, are the incremental positives; broad commercial coverage still lags.

What changed

This is the first edition of this recap, so there's no prior week to measure against. Two things are genuinely new signals worth carrying forward: the generic-drug tariff threat escalated from talk to a specific timeline (100% in August 2027, 200% the year after), and CMS formalized the return of the CMR completion rate to Star Ratings for 2027. One honest note on the drug-pricing side: this week's podcasts largely skipped the IRA's specific mechanics: the "pill penalty," the 2028 selected-drug list, and the Part D redesign, so the pricing debate showed up through tariffs and patents rather than Medicare negotiation. We'll flag it if that changes.